Drug intelligence / Profile preview

P2X7 antagonist (Suven Life Sciences)

Development stage: Preclinical
Lead developer: Suven Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

P2X7 antagonist is a small molecule drug candidate being developed by Suven Life Sciences for the treatment of pain and inflammation. It targets the P2X7 purinoceptor, an ATP-gated ion channel that plays a critical role in the activation of the NLRP3 inflammasome and the subsequent release of pro-inflammatory cytokines such as IL-1β and IL-18. By inhibiting this receptor, the drug aims to mitigate neuroinflammation and chronic pain signaling. The program is currently in the lead optimization stage of preclinical development within Suven's research pipeline.

Targets

P2RX7 (P2X purinoceptor 7)

Beyond the preview

Go deeper on P2X7 antagonist (Suven Life Sciences).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P2X7 antagonist (Suven Life Sciences).

Explore the full profile